Podcasts about respiratory syncytial virus

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to patients in such a way, offering hope for those suffering from conditions previously thought untreatable. This development is not just about treating one disorder; it opens up a world of possibilities for addressing various genetic diseases. By precisely editing genes at their source, scientists are paving the way for therapies that could revolutionize how we approach genetic disorders. Shifting gears to regulatory news, the FDA has granted accelerated approval to a new Alzheimer's drug that targets amyloid plaques in the brain. This drug, through its unique mechanism of action, aims to slow down cognitive decline in patients diagnosed with early-stage Alzheimer's disease. While there remains debate about the amyloid hypothesis itself, this approval signals a hopeful step forward in treating a condition that affects millions worldwide. As researchers continue to explore and understand Alzheimer's pathology, such approvals encourage further innovation and investment into neurodegenerative research. In clinical trial news, a biotech company has announced promising results from its Phase 3 trial of an mRNA-based vaccine for respiratory syncytial virus (RSV). The trial demonstrated high efficacy in preventing severe RSV infections among older adults, a population particularly vulnerable to this virus. These results not only underscore the versatility of mRNA technology but also highlight how quickly platforms developed during the COVID-19 pandemic can be adapted for other infectious diseases. This advancement suggests a future where rapid response to emerging viral threats becomes more feasible. Meanwhile, in the realm of oncology, there's been an exciting development with a novel immunotherapy showing potential in treating pancreatic cancer. This approach involves modifying patients' own immune cells to better recognize and attack cancer cells, a technique known as CAR-T cell therapy. Although traditionally successful in blood cancers, applying it to solid tumors like pancreatic cancer has been challenging due to their dense and protective tumor microenvironments. Early data indicate that this immunotherapy may penetrate these barriers more effectively, offering new hope for patients facing one of the deadliest forms of cancer. On a broader scale, the industry continues to see an increase in collaborative efforts between pharmaceutical giants and smaller biotech firms. These partnerships are essential for fostering innovation and speeding up drug development processes. By combining resources and expertise, companies can tackle complex health challenges more efficiently than ever before. Such collaborations also reflect an industry trend towards open innovation models that prioritize agility and shared knowledge over traditional competition. Finally, let's touch on an emerging trend that's capturing attention: personalized medicine's growing influence on drug development strategies. With advances in genomics and data analytics, pharmaceutical companies are increasingly tailoring therapies to individual patient profiles rather than adopting a one-size-fits-all approach. This shift not only improves treatment efficacy but also reduces the likelihood of adverse reactions, ultimately leading to better patient outcomes and more efficient healthcare systems. These stories illustrate an industry at the cutting edge of science and technology, driven by a relentless pursuit of new ways to improve human health. Each breakthrough not only represents progress but also carries profound implications for future research directions and therapeutic possibilities. That's all for today's edition of Pharma Daily. Stay tuned as we continue to bring you more updates on these exciting developments in pharmaceuticals and biotechnology. Thank you for listening, and we'll be back soon with more insights from this dynamic field.Support the show

RSV stands for Respiratory Syncytial Virus, which is a highly contagious respiratory virus that infects the respiratory tract and lungs. Is it dangerous? - RSV adalah singkatan dari Respiratory Syncytial Virus, yaitu virus pernapasan yang sangat menular yang menginfeksi saluran pernapasan dan paru-paru. Apakah berbahaya?

Dr. Margarita Fedorova discusses whether a vaccine ingredient is quietly protecting the brain.  Show citation:  Taquet M, Todd JA, Harrison PJ. Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections. NPJ Vaccines. 2025;10(1):130. Published 2025 Jun 25. doi:10.1038/s41541-025-01172-3 Show transcript:  Dr. Margarita Fedorova:  Welcome to Neurology Minute. My name is Margarita Fedorova, and I'm a neurology resident at the Cleveland Clinic. Today we're exploring a study that raises a compelling question. Could a vaccine ingredient be quietly protecting the brain? A recent study by Taquet et al., published in npj Vaccines in 2025, investigated whether vaccination with an AS01-adjuvanted vaccine is associated with a lower risk of dementia. You might know it as the immune-boosting ingredient in Shingrix, the shingles vaccine, and Arexvy, the new RSV vaccine. We already know from prior work that the Shingrix vaccine was associated with a reduced risk of dementia, but the question this paper asks is why. Is it because preventing shingles itself protects the brain, or is there something specific about the adjuvant that's doing the work? To answer this, the researchers used a large US electronic health record database comparing over 35,000 people who received the AS01-adjuvanted RSV vaccine, over 100,000 who received the AS01-adjuvanted shingles vaccine and over 78,000 who received both. Each matched against individuals who got the seasonal flu vaccine instead. The findings were interesting. People who received the RSV vaccine had a 29% lower risk of new dementia diagnosis over the following 18 months. Those who received the shingles vaccine had an 18% increase in time without dementia, and those who received both had a 37% increase in dementia-free time. Here's a key insight. Both vaccines target completely different viruses, but both contain the same adjuvant. The fact that a similar protective signal was seen with both suggests the benefit may not be about which virus is prevented, and it may be about the AS01 itself. Why might an adjuvant protect the brain? AS01 contains two active components, monophosphoryl lipid A, known as MPL, and QS21. Together they activate macrophages and dendritic cells, triggering cascade that includes a production of interferon gamma. In animal models, stimulation of a receptor called toll-like receptor 4, which MPL activates, has been shown to reduce Alzheimer's-like pathology. The authors also point out that the protective effect appears within just a few months of vaccination, which is hard to explain purely by prevented infections and may point instead to a direct immunological mechanism. Very important caveat. This is an observational study, not a randomized trial, so we can't prove causation. There was also uncertainty about which brand of RSV vaccines some patients received, which could affect the strength of the AS01-specific conclusion. And with all of the dementia studies, it's unclear whether the vaccines prevent dementia or delay its onset. Though even a delay would be clinically meaningful given how few tools we have. What does this mean for clinical practice? For now, it doesn't change your vaccination recommendations. Both Shingrix and Arexvy already indicated in appropriate patients for the primary purposes, but it adds an intriguing possible benefit when counseling patients who ask about vaccines. And it opens the door to a genuinely exciting question. If AS01 has neuroprotective properties, could it be studied in a therapeutic target in its own right? That's the Neurology Minute for today. Keep exploring and we'll see you next time. If you want to read more, please find the paper by Maxime Taquet, et al., titled Lower Risk of Dementia with AS01-Adjuvanted Vaccination Against Shingles and Respiratory Syncytial Virus Infections, published in npj Vaccines in June 2025. 

Kgomotso Modise, standing in for Clement Manyathela, speaks to Diane Buron, the head of vaccines medical at Sanofi South Africa, to discuss the disease and how it affects children. You’re listening to The Clement Manyathela Show on 702. Clement Manyathela makes sense of the news of the day while sharing information to guide you through daily life. As your morning friend, he tackles both the serious and the light-hearted on your behalf. Thank you for listening. Listen live on Primedia+ weekdays from 9 am to 12 pm (South African time) on 702 https://buff.ly/gk3y0Kj For more from the show and catch-up podcasts, visit Primedia+ https://buff.ly/XijPLtJ Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Keep the conversation going online: 702 on Facebook https://www.facebook.com/TalkRadio702 702 on TikTok https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

Aubrey Masango talks to Dr Shaakira Abrahams, scientist and vaccines medical manager at Sanofi, about respiratory syncytial virus (RSV), the dangers it poses to infants, and the best ways to prevent it. You’re listening to The Aubrey Masango Show with Aubrey Masango, where real conversations meet expert insights – from politics, to life, personal finance, and more. Catch the show live on 702 weekdays from 8 pm to midnight, or on CapeTalk from 8 pm to 9 pm (South African time) Thanks for listening. Find more from the show and catch-up podcasts on Primedia+ and subscribe to the 702 newsletters for more. Keep the conversation going online: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/capetalkza/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello note the uncertain future of the National Science Foundation amid shifting U.S. funding priorities and governance; the rise of China as a global research powerhouse; ongoing advances and controversies in vaccines shaped by the World Health Organization and the Centers for Disease Control and Prevention; vaccine policy battles in Florida; European approval of the moderna mCOMBRIAX, COVID-19 and influenza vaccine, the mounting evidence supporting preventive vaccination strategies including that for HPV and the HepB birth dose; the spread of drug-resistant infections and the resurgence of HIV in Zambia; and the enduring public trust in scientists despite political turbulence, before Dr. Griffin deep dives into the measles outbreak, recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, the efficacy of the influenza vaccine for children, PEMGARDA authorized use for certain immunocompromised individuals where to find PEMGARDA, how to access and pay for Paxlovid, use of remdesivir for RSV, how administration of Paxlovid did not affect hospitalization of high-risk vaccinated patients, where to go for answers about long COVID-19, if SARS-CoV-2 infection may facilitate EBV reactivation, exercise for treating long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Entire NSF science advisory board fired by Trump administration (Nature) United States v. Arthrex, Inc.(Harvard Law Review) United States v. Arthrex Inc. [SCOTUSbrief] (Federalist Society) China could be the world's biggest public funder of science within two years (Nature) The Vaccine Skeptic in Trump's New C.D.C. Leadership Team (NY Times) World Immunization week: Largest catch-up initiative delivers over 100 million childhood vaccinations (WHO) Pigs are flying!: Florida Republicans refuse to take up DeSantis bill loosening vaccine mandates (NY Times) Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19(moderna) America First! AIDS Creeps Back in Parts of Zambia, a Year After U.S. Cuts to H.I.V. Assistance (NY Times) Emergence of Extensively Drug-Resistant Shigellosis — United States, 2011–2023 (CDC: MMWR) Scientists Esteemed by Public, with Vaccine Scientists Seen as Similar to Scientists in General (Annenberg: Public Policy Center, University of Pennsylvania) RFK Jr. is holding up $600M in vaccines for poor countries (Politico) Trump Withdraws Nomination of Casey Means for Surgeon General (NY Times) What? Benefit of preventive strategies like vaccination? Incidence of human papillomavirus infections in women aged 27 years and older in the US: A federated data network study (International Journal of Infectious Diseases) Economic Impact of Delaying the Infant Hepatitis B Vaccination Schedule (JAMA Pediatrics) Impact of Removing the Universal Hepatitis B Birth-Dose Vaccination in the US (JAMA Pediatrics) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Dangers of measles infection (NY Times) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (Xofluza) Influenza Vaccination Coverage Among Nursing Home Residents and Health Care Personnel — United States, 2024–25 Influenza Season (CDC: MMWR) Pediatric Vaccine Effectiveness Against Influenza Hospitalization And Outpatient Visits: 2021–2024 (Pediatrics) Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022–2024 (Pediatrics) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Respiratory Diseases (Yale School of Public Health) Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study (LANCET: Infectious Diseases) First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients (JID) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients(NEJM) Same Pill, Different Impact — Reassessing the Efficacy of Nirmatrelvir–Ritonavir(NEJM) Paxlovid doesn't reduce hospitalization, death rates in vaccinated high-risk COVID outpatients, trial shows (CIDRAP) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia: Columbia University Irving Medical Center) The answers: Long COVID Acute COVID-19 is associated with altered CD8 T-cells indicative of impaired ability to control Epstein–Barr virus reactivation (Medical Microbiology and Immunology) Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled Trial (Journal of Cachexia, Sarcopenia and Muscle) Reaching out to US house representative Letters read on TWiV 1318 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

On episode #105 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 4/9 – 4/22/26. Host: Daniel Griffin and Sarah Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients (NEJM) Same Pill, Different Impact — Reassessing the Efficacy of Nirmatrelvir–Ritonavir (NEJM) Paxlovid doesn't reduce hospitalization, death rates in vaccinated high-risk COVID outpatients, trial shows (CIDRAP) Risk of Guillain–Barré Syndrome after Laboratory-Confirmed Dengue Infection (NEJM) A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage (JID) First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients (JID) Bacterial Tetanus Surveillance — United States, 2009–2023 (CDC: MMWR) Notes from the Field: Tetanus in Four Children — Idaho, Minnesota, Missouri, and Wisconsin, 2024 (CDC: MMWR) Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults (JAMA) Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials (Infection) Methicillin-Resistant Staph Aureus (MRSA) Nasal Swab Utilization as a Predictor for MRSA Skin & Soft Tissue Infections: A Systematic Review and Meta-analysis (OFID) Practice variation, outcomes and definitions of suppressive antimicrobial therapy for prosthetic joint infections: a systematic review and expert consensus statement (CIC) Efficacy and safety of VPM1002 and Immuvacin preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial) (BMJ) Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis (CID) Do C-Reactive Protein Measurements Predict Treatment Failure in Native Vertebral Osteomyelitis? (OFID) Fungal The Last of US Season 2 (YouTube) Rising burden of severe pediatric coccidioidomycosis: a 25-year single-center study (Journal of the Pediatric Infectious Diseases Society) Candida glabrata emerges as the most common cause of candidemia: analysis of a large hospital-based database, United States, 2016–2024 (CID) Test Performance and Clinical Utility of the cobas® eplex Blood Culture Identification Fungal Pathogen Panel (OFID) Cutaneous Paraconiothyrium cyclothyrioides Infection in Lung Transplant Recipient, Georgia, USA (Emerging Infectious Diseases) Azole Resistance in Aspergillus fumigatus From Diverse Environments in Ohio, United States, Is Primarily Driven by TR34/L98H and TR46/Y121F/T289A Environmental Signatures (OFID) Parasitic Fatal Donor-Derived Disseminated Acanthamoeba Infection in a Liver Transplant Recipient (OFID) Miscellaneous Host–microbiome archetypes differentiate infection from pathogen carriage in the human lower airway (Nature Communications) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

In his weekly clinical update, Dr. Griffin and Vincent Racaniello are distressed by RFK Jr's testimony in front of Congress, surges in rotavirus infections and the staggering number of people who believe in unproven claims about vaccines and science, before Dr. Griffin then deep dives into the measles outbreak, recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, the fatal consequences of measles infection, prevalence of influenza and other respiratory infections in dead people, PEMGARDA authorized use for certain immunocompromised individuals where to find PEMGARDA, how to access and pay for Paxlovid, results from a human RSV challenge study, where to go for answers about long COVID-19, negatively associated school-related outcomes in children and adolescents with long COVID, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Kennedy denies being sidelined by the White House (Politico) Kennedy continued to back away from his criticismof the measles vaccine (NY Times) Rotavirus surges after ACIP removes recommendation for vaccine(Discovermagazine) 'Staggering' number of people believe unproven claims about vaccines, raw milk and more (Nature) Health is confronting division, confusion, and competing influences (Edelman) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard(South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) UtahMeasles Dashboard (Utah Department of Health and Human Services) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Dangersof measles infection (NY Times) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots(CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) Prevalenceof influenza and other respiratory viral infections in deceased persons: a population-based observational study over four influenza seasons (Clinical Microbiology and Infection) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Respiratory Diseases (Yale School of Public Health) Maternal RSV vaccination and reduced risk of hospitalisation for babies in England, 2024/25 (ESCMID) Viral dynamics of the Respiratory Syncytial Virus during experimental human challenge: insights for transmission and protection(JID) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Clinical and economic benefits of seasonal COVID-19 vaccination in Germany: results from the ROUTINE-COV19 Study, September 2022 to March 2024 (Eurosurveillance) Effectiveness and safety of molnupiravir among patients with mild to moderate COVID-19: a prospective, observational, cohort study (Scientific Reports) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding CoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Divergent inflammatory and neurology-related protein levels in long COVID following primary and breakthrough SARS-CoV-2 infections (Communications Medicine) School Difficulties and Long COVID in Children and Adolescents (Academic Pediatrics) Reaching out to US house representative Letters read on TWiV 1316 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Respiratory Syncytial Virus, or RSV, a common and highly contagious respiratory virus that can be mistaken for a cold or influenza. As Australia heads into winter, it is raising concern, especially for older adults and young children. In response, the federal government is rolling out free vaccinations for eligible seniors. In this episode, Associate professor and paediatrician Dr Habib Bhurawala breaks down what RSV is, who is at risk, and how families can stay protected this season.

The Federal Government has announced free RSV vaccinations for older Australians, in a push to better protect those most at risk from the potentially deadly respiratory virus. - Magkakaloob ng libreng bakuna laban sa RSV o Respiratory Syncytial Virus ang Federal Government para sa mga nakatatandang Australiano, bilang bahagi ng hakbang na protektahan ang mga pinaka-nanganganib sa nakamamatay na respiratory virus.

This audio explains who can have the RSV vaccination from Spring 2026 and how they can get their vaccine. It also signposts other sources of information. You can find this and other alternative formats of national invitations at www.england.nhs.uk/rsv-invites A full transcript of this episode is available on our website - www.england.nhs.uk/long-read/getti…sv-vaccination/

Relebogile Mabotja speaks to Dr Shaakira Abrahams a Scientist and Vaccines Medical Manager at Sanofi about RSV (Respiratory Syncytial Virus), how it affects children, and what parents can do to protect their families this season.702 Afternoons with Relebogile Mabotja is broadcast live on Johannesburg based talk radio station 702 every weekday afternoon. Relebogile brings a lighter touch to some of the issues of the day as well as a mix of lifestyle topics and a peak into the worlds of entertainment and leisure. Thank you for listening to a 702 Afternoons with Relebogile Mabotja podcast. Listen live on Primedia+ weekdays from 13:00 to 15:00 (SA Time) to Afternoons with Relebogile Mabotja broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/2qKsEfu or find all the catch-up podcasts here https://buff.ly/DTykncj Subscribe to the 702 Daily and Weekly Newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

In this podcast, featuring audio from an expert roundtable video module, listen as 3 multidisciplinary faculty, Tracey Q. Davidoff, MD, FCUCM; Carina Marquez, MD, MPH; and Jeffrey D. Whitman, MD, MS, discuss the benefits of diagnosing respiratory syncytial virus (RSV) and optimal testing strategies. Topics covered include:The annual burden of RSV and the benefits of diagnosisWhom to test and what diagnostic techniques to useLogistical considerations for implementationPotential benefits of RSV testingFor the full video module and to download the accompanying slides, visit the program page for this episode:https://bit.ly/3MrXTpIPresenters:Tracey Q. Davidoff, MD, FCUCMAttending PhysicianBaycare Urgent CareAssistant Professor, Family MedicineFlorida State University College of MedicineTallahassee, FloridaCarina Marquez, MD, MPHAssociate Professor of MedicineDivision of HIV, Infectious Diseases and Global MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaJeffrey D. Whitman, MD, MSCo-Director of Clinical MicrobiologyAssociate ProfessorDepartment of Laboratory MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send Zorba a message!Dr. Zorba Paster on the RSV outbreak and what you need to know about the different vaccines available.(Recorded November 2, 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

Send Zorba a message!Dr. Zorba Paster on the RSV outbreak and what you need to know about the different vaccines available.(Recorded November 2, 2025)Support the showProduction, edit, and music by Karl Christenson Send your question to Dr. Zorba (he loves to help!): Phone: 608-492-9292 (call anytime) Email: askdoctorzorba@gmail.com Web: www.doctorzorba.org Stay well!

Lung Health and Respiratory Syncytial Virus: Podcast of a Patient–Physician Discussion Based on Insights from a Patient Advisory Board Meeting This podcast is published open access in Infectious Diseases and Therapy and is fully citeable. You can access the original published podcast article through the Infectious Diseases and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40121-025-01216-0. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Vidcast:  https://www.instagram.com/p/DOweKVlCSKY/A single RSV vaccination is protective for vulnerable adults through 2 consecutive RSV seasons.  This the conclusion of a multicenter, collaborative study headed by investigators at Vanderbilt University.  They studied 6958 persons 60 years or older hospitalized with respiratory illness in 20 states from 2023 into 2025.The vaccine effectiveness for preventing a hospitalization with Respiratory Syncytial Virus was 69% during the first year following vaccination and 48% during the second year yielding an average effectiveness over the 2 years of 58%.  The year-to-year change was not significant.Drilling down on the study population, the 2 season vaccine effectiveness was lower for immunocompromised patients at 30% compared with 67% for the immunocompetent and lower at 58% or those with cardiovascular disease versus 80% for those without it.Work is now ongoing to determine when individuals with complicating medical conditions such as immunosuppression and/or cardiovascular  disease should receive RSV boosters. Also expect to see recommendations from infectious disease specialists regarding when otherwise healthy older individual should receive boosters.https://jamanetwork.com/journals/jama/fullarticle/2838490#rsv #vaccination #hospitalization #immunosuppression #cardiovascular

On episode #88 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 8/19/25 – 8/27/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination (CDC: MMWR) Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial (LANCET: HIV) Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial (CID) Bacterial Exposure to suppressive antibiotic therapy in women with recurrent urinary tract infections and severity of infections: a retrospective population-based cohort study (BMJ Open) Effectiveness and safety of antibiotics in kidney transplant recipients with asymptomatic bacteriuria: a systematic review and meta-analysis of randomized controlled trials (OFID) Epidemiological, temporal, and geographic trends of leptospirosis in the United States, 2014–2020 (PLoS Neglected Tropical Diseases) Performance of Tongue Swabs for Tuberculosis Diagnosis in Hospitalized Children Under 5 Years of Age (OFID) Fungal The Last of US Season 2 (YouTube) Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults (LANCET: Infectious Diseases) Parasitic Outcomes of Military Blood Donors at Joint Base San Antonio with Reactive Trypanosoma cruzi Antibody Screening (OFID) Cutaneous acanthamoebiasis: Two Cases Highlighting Diverse Histopathologic Findings (Journal of Cutaneous Pathology) Miscellaneous Linezolid-related Optic Nerve Disorders: Insight from a Pharmacovigilance Analysis of the U.S. FDA Adverse Event Reporting System (OFID) Extreme variability in linezolid concentrations in the ICU: A case for routine therapeutic drug monitoring (American Journal of Health-System Pharmacy) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

The Department of Health has today announced the details of a new Immunisation Programme for Respiratory Syncytial Virus (or RSV), which will run throughout this coming winter. We get all the details from Ellen Crushell, the Deputy Chief Medical Officer at the Department of Health.

Respiratory Syncytial Virus (RSV) significantly impacts adults, especially those over age 60 and those with chronic conditions.In this podcast, nurse practitioners Drs. Carrico and Stevenson discuss the underestimated burden of RSV. The podcast also explores practical strategies for increasing vaccine uptake that you can apply to your practice starting today so that you can protect your patients against RSV.Listen as they discuss:The Burden of Adult RSVRSV Vaccines for Adults: Data and RecommendationsRSV Vaccine UptakePractical Strategies to Increase RSV Vaccine Uptake Faculty:Dr. Ruth Carrico is a family nurse practitioner and senior consultant with Carrico & Ramirez, PLLC focused on infectious diseases, infection prevention and control, and vaccinology.  She is based in Louisville, Kentucky and is a Professor, adjunct faculty, with the University of Louisville School Medicine, Division of Infectious Diseases. Dr. Carrico has received training specific for healthcare epidemiology at the Centers for Disease Control and Prevention (CDC) in conjunction with the Rollins School of Public Health at Emory University in Atlanta and the Society for Healthcare Epidemiology of America (SHEA). Dr. Carrico has worked in the field of infectious diseases and infection control for more than thirty years.  Dr. Carrico also maintains a clinical practice focused on vaccines, vaccination, and immunization processes.Dr. Audrey M. Stevenson is a family nurse practitioner with over 40 years of clinical, public health, and leadership experience. Dr. Stevenson, who holds a master of public health and master of nursing degrees, received her doctorate in public health from the University of Utah. She formerly worked in public health for over 34 years and was the former Division Director of Family Health and Clinical Services of the Salt Lake County Health Department in Salt Lake City, Utah. She currently works as a consultant and teaches graduate FNP and MPH students at two universities. Dr. Stevenson is also a member of the statewide vaccine advisory board, where she collaborates on vaccine policies and recommendations for the state. Previously, Dr. Stevenson served as Vaccination Branch Director for the COVID-19 Incident Command for Salt Lake County, where she directed the vaccination strategies for 1.2 million residents of Salt Lake County. She has been a vaccine champion for over 30 years. Learn more:Download this practical infographic to help you integrate RSV vaccination into your clinical practice.https://bit.ly/43mzacqFor more information for nurses, subscribe to the PCE podcast channel on your favorite player! 

Respiratory Syncytial Virus (RSV) significantly impacts adults, especially those over age 60 and those with chronic conditions.In this podcast, nurse practitioners Drs. Carrico and Stevenson discuss the underestimated burden of RSV. The podcast also explores practical strategies for increasing vaccine uptake that you can apply to your practice starting today so that you can protect your patients against RSV.Listen as they discuss:The Burden of Adult RSVRSV Vaccines for Adults: Data and RecommendationsRSV Vaccine UptakePractical Strategies to Increase RSV Vaccine UptakeFaculty:Dr. Ruth Carrico is a family nurse practitioner and senior consultant with Carrico & Ramirez, PLLC focused on infectious diseases, infection prevention and control, and vaccinology.  She is based in Louisville, Kentucky and is a Professor, adjunct faculty, with the University of Louisville School Medicine, Division of Infectious Diseases. Dr. Carrico has received training specific for healthcare epidemiology at the Centers for Disease Control and Prevention (CDC) in conjunction with the Rollins School of Public Health at Emory University in Atlanta and the Society for Healthcare Epidemiology of America (SHEA). Dr. Carrico has worked in the field of infectious diseases and infection control for more than thirty years.  Dr. Carrico also maintains a clinical practice focused on vaccines, vaccination, and immunization processes.Dr. Audrey M. Stevenson is a family nurse practitioner with over 40 years of clinical, public health, and leadership experience. Dr. Stevenson, who holds a master of public health and master of nursing degrees, received her doctorate in public health from the University of Utah. She formerly worked in public health for over 34 years and was the former Division Director of Family Health and Clinical Services of the Salt Lake County Health Department in Salt Lake City, Utah. She currently works as a consultant and teaches graduate FNP and MPH students at two universities. Dr. Stevenson is also a member of the statewide vaccine advisory board, where she collaborates on vaccine policies and recommendations for the state. Previously, Dr. Stevenson served as Vaccination Branch Director for the COVID-19 Incident Command for Salt Lake County, where she directed the vaccination strategies for 1.2 million residents of Salt Lake County. She has been a vaccine champion for over 30 years. Learn more:Download this practical infographic to help you integrate RSV vaccination into your clinical practice.https://bit.ly/43mzacqFor more information for nurses, subscribe to the PCE podcast channel on your favorite player! 

In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses vaccination trends, the changes COVID-19 vaccine recommendations for children and pregnant women, easing of vaccination exemptions in Texas, the ongoing measles outbreak globally before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections the Wasterwater Scan dashboard, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines and concern as confirmed diagnosis of COVID-19 rise here and in China, different mechanisms by which to reduce transmission of respiratory pathogens, the May 22 VRBPAC COVID-19 vaccine meeting, where to find PEMGARDA, prolonged steroid and antibiotic therapies, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions, how spike protein may alter mast cells and the immune response and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Vaccination trends (CDC: Respiratory Illnesses) Weekly COVID-19 Vaccination Dashboard (CDC: COVIDVaxView) RFK Jr ends coronavirus shot recommendation for healthy children and pregnant women (Washington Post) Characteristics of Children Ages 1–17 Who Died of COVID-19 in 2020–2022 in the United States (American Academy of Pediatrics) RFK Jr.'s War on Children (Paul Offit: Beyond the Noise) AAP analyzes pediatric COVID-19 hospitalizations from 2020-'24 (American Academy of Pediatrics) COVID-19–Associated Hospitalizations among Children and Adults — COVID-NET (CDC: National Center for Immunizations and Respiratory Diseases) COVID-19–Associated Hospitalizations among Children and Adults — COVID-NET (CDC: National Center for Immunizations and Respiratory Diseases) Long COVID in Children (CDC: NCHS) Long COVID Prevalence and Associated Activity Limitation in US Children (JAMA Pediatrics) The C.D.C. Now Says Healthy Kids Don't Need Covid Shots. Is That True? (NY Times) U.S. Will No Longer Recommend Covid Shots for Children and Pregnant Women (NY TImes) Gregg Abbott (AP News) US school-entry vaccination rates fall as exemptions keep rising (AP News) Whooping cough cases are rising again in the US (AP News) Amid measles outbreak, Texas is poised to make vaccine exemptions for kids easier (AP News) Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza (JAMA Network Open) USDA reported H5N1 bird flu detection in wild birds (CDC: Avian Influenza) USDA reported H5N1 in poultry (CDC: Avian Influenza) HPAI Confirmed Cases in Livestock (USDA Animal and Plant Health Inspections Service) H5 bird flu: current situation (CDC: Avian Influenza) Bird flu (CDC: Avian Influenza) Measles cases and outbreaks (CDC Rubeola) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Measles vaccine recommendations from NYP (jpg) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Respiratory syncytial virus: an under-recognized healthcare-associated infection (Infection Control & Hospital Epidemiology) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (biRxiV) New Covid variant NB.1.8.1 detected at US airports amid rise in cases U.S. reports cases of new COVID variant NB.1.8.1 behind surge in China (CBS News) WHO TAG-VE Risk Evaluation for SARS-CoV-2 Variant Under Monitoring: NB.1.8.1 (WHO) New COVID variant NB.1.8.1 detected at US airports amid rise in cases (The Economic Times: News) Infection Control Guidance: SARS-CoV-2 (CDC: COVID-19) Isolating the burden of transmission-based precautions for COVID-19 (Infection Control & Hospital Epidemiology) A pilot study of coughing into the shirt to disrupt respiratory pathogen transmission (International Journal of Emergency Medicine) Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants (JID) FDA panel is split on updates to COVID shots as questions loom for fall vaccinations(AP News) COVID-19 Vaccines (2025-2026 Formula) for Use in the United States Beginning in Fall 2025(FDA) Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States (CDC: COVID-19) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Clinical effectiveness of oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during Omicron JN.1 subvariant wave(Pneumonia) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Patients (CID) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Steroids,dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19 (Thorax) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Spike proteins of coronaviruses activate mast cells for degranulation via stimulating Src/PI3K/AKT/Ca2+ intracellular signaling cascade (Journal of Virology) Reaching out to US house representative Letters read on TWiV 1222 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

On episode #80 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 4/24/25 – 5/7/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Incidence and Timing of Epstein–Barr Virus Whole Blood DNAemia in Epstein–Barr Virus-Mismatched Adult and Pediatric Solid Organ Transplant Recipients (Transplant Infectious Disease) Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023–2024 (American Academy of Pediatrics) Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants (Influenza and other respiratory viruses) Hospital admissions of respiratory infections in infants plungewith nirsevimab RSV antibody (CIDRAP) Time to antiviral treatment in mild–moderate COVID-19 in the emergency department (Internal and Emergency Medicine) Delays in COVID antiviral receipt raised risk of poor outcomes after ED visits by 18%, data suggest (CIDRAP) Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV (MMWR) Bacterial Validation and clinical implementation of cerebrospinal fluid C-reactive protein for the diagnosis of bacterial meningitis (LANCET: Regional Health) Bridging to transplant: TDM-Guided Outpatient Dalbavancin Therapy in Chronic Granulomatous Disease with deep-seeded Inoperable Abscesses over 11 Months (OFID) Nitrites for Urinary Tract Infection—Time to Say Goodbye? (JAMA: Internal Medicine) Fungal The Last of US Season 2 (YouTube) High Mortality and Associated Risk Factors in Kidney Transplant Recipients with Cryptococcosis – A Nationwide Cohort Study Over a Decade Using USRDS Data (OFID) Use of Dog Serologic Data for Improved Understanding of Coccidioidomycosis (JID) Parasitic Performance of a novel P. falciparum rapid diagnostic test in areas of widespread hrp2/3 gene deletion (CID) Prevalence of Anopheles stephensi in the Horn of Africa: a systematic review and meta-analysis (BMC Infectious Diseases) Raising awareness of Demodex mites: a neglected cause of skin disease (Infection) Miscellaneous Scientific Integrity Under Threat: The Role of the IDSA, PIDS, and SHEA Journals in an Evolving Political Landscape (CID) Reasoning on Rounds Volume 2: a Framework for Teaching Management Reasoning in the Inpatient Setting (Journal of General Internal Medicine) Billing for and documentation of provider-to-provider interprofessional consults in infectious diseases (Journal of the Pediatric Infectious Diseases Society) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Today we are exploring Respiratory Syncytial Virus including its spread, its treatment and impact on families.This podcast was created with the support of our sponsor Sanofi. Dr Rama Kandasamy is a paediatrician working at the Sydney Childrens Hospital network and the National Centre for Immunisation Research and Surveillance.He emphasises the importance of early childhood immunisations and is today's special guest.

Do you know who is most at risk of severe respiratory syncytial virus (RSV) disease and associated complications? Credit available for this activity expires: 2/28/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002275?ecd=bdc_podcast_libsyn_mscpedu

Should I be worried about bird flu? How dangerous is the new COVID variant? How does bird flu spread to humans? Is bird flu going to become a pandemic? What is HMPV? AMA's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH, discusses the "mystery virus" human metapneumovirus, that HMPV is not new, and shares trends in seasonal influenza and COVID-19 cases. Also covering the latest bird flu news of H5N9 on a California duck farm, as well as a raw pet food recall and the dangers of H5N1 for dogs and cats. American Medical Association CXO Todd Unger hosts.

This podcast provides information on the NHS respiratory syncytial virus (RSV) offer for eligible people aged 75 to 79 years, including those who have recently turned 80. Read more at www.nhs.uk/rsv-vaccine A transcript of this episode is available on our website - https://www.england.nhs.uk/long-read/nhs-respiratory-syncytial-virus-rsv-vaccination/

Jake Noble, PharmD, MPH reviews management of respiratory syncytial virus in patients undergoing allogeneic hematopoietic stem cell transplant.   For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.  You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

Dr Pablo Sanchez, Lindsey Glaze, and members of our clinical pharmacy program visit the studio as we consider respiratory syncytial virus (RSV) and share updates on its management and prevention. We hope you can join us!

Respiratory syncytial virus (RSV) is a common infection that may cause severe illness in infants, young children, and older adults. Kathleen A. Linder, MD, of the VA Ann Arbor Healthcare System, discusses therapies to prevent severe RSV illness with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content: Therapies to Decrease Severe Respiratory Syncytial Virus Illness Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus

To have your question featured in a future video, please email: questions@drmdc.health

RSV stands for "Respiratory Syncytial Virus". We wade into a description of the disease plus some information about the vaccines. Finally, what American sport draws its players and fans from the older ages than any other? PICKLEBALL! Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+)   Inspired by: "MEDICARE FOR THE LAZY MAN 2024; Simplest & Easiest Guide Ever!" on Amazon.com. Return to leave a short customer review & help future readers. Official website: https://www.MedicareForTheLazyMan.com.

RSV season is upon us, and there are a number of new exciting developments in the prevention of RSV to discuss! Listen in, as Prof Asha Bowen chats to Kristin and Natalie about the newest innovations in RSV immunisation and vaccination. Prof Asha Bowen is a paediatric infectious disease specialist and clinician-researcher at Perth Children's Hospital and Telethon Kids Institute. She is Head of Department of Infectious Diseases at Perth Children's Hospital. ATAGI statement in the use of Arexvy in older Australians NCIRS FAQs relating to RSV Information relating to WA RSV Immunisation Program Information relating to the QLD RSV Immunisation Program Clinician Guide to the NSW RSV Immununisation Program

In this episode, Angela Branche, MD, FIDSA, and Jewel Mullen, MD, MPH, MPA, FACP, address commonly asked questions about the RSV vaccine, including:Considerations for vaccine eligibilityRecommendations for pregnant personsVaccine administration based on RSV seasonalityUse of the vaccine in persons receiving immunosuppressive medicationsSafety data (eg, risk of serious adverse events)Natural immunity of RSVVaccine cost and insurance coverageFaculty:Angela Branche, MD, FIDSAAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkJewel Mullen, MD, MPH, MPA, FACPAssociate Dean for Health EquityAssociate Professor of Population Health and Internal MedicineUniversity of Texas at Austin Dell Medical SchoolAustin, TexasContent based on a CME program supported by an educational grant from GlaxoSmithKline.Follow along with a downloadable slideset at:https://bit.ly/44vCnFuLink to full program: https://bit.ly/3WvSY9ZTo get access to all of our new podcasts, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Angela Branche, MD, FIDSA, explores the burden of RSV disease in older adults, including:RSV seasonality and disease burdenSymptoms and complications of RSV infectionOlder age as a key risk factor for severe RSV disease and complications (eg, pneumonia, hospitalization)Comorbidities associated with increased risk of RSV hospitalizationRSV hospitalization rates among different racial and ethnic minority groups and socioeconomic statuses Faculty:Angela Branche, MD, FIDSAAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkContent based on a CME program supported by an educational grant from GlaxoSmithKline.Follow along with a downloadable slideset at: https://bit.ly/44vCnFuLink to full program: https://bit.ly/3WvSY9ZTo get access to all of our new podcasts, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify

In this episode, Jewel Mullen, MD, MPH, MPA, FACP, discusses strategies for implementing RSV vaccines into practice, with an emphasis on:Understanding the reasoning for Advisory Committee on Immunization Practices RSV vaccine recommendations Factors that influence vaccine uptake and patient decision-makingConsiderations for patient and healthcare professional vaccine hesitancy Building vaccine confidence in both patients and healthcare professionalsUsing shared decision-making models (eg, SHARE approach)Faculty:Jewel Mullen, MD, MPH, MPA, FACPAssociate Dean for Health EquityAssociate Professor of Population Health and Internal MedicineUniversity of Texas at Austin Dell Medical SchoolAustin, TexasContent based on a CME program supported by an educational grant from GlaxoSmithKline.Follow along with a downloadable slideset at:https://bit.ly/44vCnFuLink to full program:https://bit.ly/3WvSY9ZTo get access to all of our new podcasts, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Which states have found bird flu in dairy cows? Why is measles coming back? What states are having a measles outbreak? When is respiratory virus season over? Our guest is AMA's Vice President of Science, Medicine and Public Health, Andrea Garcia, JD, MPH. American Medical Association CXO Todd Unger hosts.

Respiratory syncytial virus is a viral illness that usually causes mild, cold-like symptoms. RSV vaccine can help prevent lower respiratory tract disease caused by RSV. This podcast will discuss the use of the RSV vaccine in adults and pregnancy.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Drs. Kenneth Chinsky and Angela R. Branche share their insights into the Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults study, for which Dr. Chinsky was part of the study group and principal investigator at his clinic in Erie, PA. They discuss the findings and what they mean for HCPs who see and care for older adults who are at risk for RSV.

This year, healthcare providers have tools to help prevent lower respiratory tract disease caused by RSV for older adults. 

This year, healthcare providers have tools to help prevent lower respiratory tract disease caused by RSV for older adults. 

The McCullough Report with Dr. Peter McCullough – As ambient aerosolized RSV virions are present in hospitals, clinics, and homes, the monoclonal antibody may backfire and enable the inhaled virion to gain access to the bronchial epithelial lining and cause worse bronchiolitis than the baby would have with their own developing natural immunity. This would explain why the efficacy for RSV hospitalization was NOT compelling from the two RCTs of Nirsevimab...

The McCullough Report with Dr. Peter McCullough – As ambient aerosolized RSV virions are present in hospitals, clinics, and homes, the monoclonal antibody may backfire and enable the inhaled virion to gain access to the bronchial epithelial lining and cause worse bronchiolitis than the baby would have with their own developing natural immunity. This would explain why the efficacy for RSV hospitalization was NOT compelling from the two RCTs of Nirsevimab...

How does tirzepatide discontinuation affect weight? Find out about this and more in today's PV Roundup podcast.

Dr. Centor discusses respiratory syncytial virus infection in adults and recently approved respiratory syncytial virus vaccines with Dr. Camille Kotton.

Did you know that RSV or Respiratory Syncytial Virus is the leading cause of hospitalizations for children under 1 year of age in the United States?, which is a very frightening prospect for any parent. Today we have our guest Catherine Giudici Lowe, former bachelor winner and Mommy of 3. She joins us to share her terrifying experience with RSV, and what she wants other parents to know about it.

Parts of the US are currently in the midst of a triple-demic, a very scary phrase, so Dr. Sydnee is here to break down the third illness: Respiratory Syncytial Virus, or RSV. It's a virus that's common among everyone, but can be dangerous for some people. Dr. Sydnee and Justin talk about what it is, why it is suddenly prevalent in adults, and what can be done to help prevent the spread (hint: wear a mask).Music: "Medicines" by The Taxpayers https://taxpayers.bandcamp.com/